14 results on '"Praça, F"'
Search Results
2. Trans-resveratrol and beta-carotene from sunscreens penetrate viable skin layers and reduce cutaneous penetration of UV-filters
- Author
-
Freitas, J. V., Praça, F. S.G., Bentley, M. V.L.B., and Gaspar, L. R.
- Published
- 2015
- Full Text
- View/download PDF
3. Nanotechnology approaches in the current therapy of skin cancer
- Author
-
Borgheti-Cardoso, L, Viegas, J, Silvestrini, A, Caron, A, Praça, F, Kravicz, M, Bentley, M, Borgheti-Cardoso, Livia Neves, Viegas, Juliana Santos Rosa, Silvestrini, Ana Vitoria Pupo, Caron, Angelo Luis, Praça, Fabiola Garcia, Kravicz, Marcelo, Bentley, Maria Vitória Lopes Badra, Borgheti-Cardoso, L, Viegas, J, Silvestrini, A, Caron, A, Praça, F, Kravicz, M, Bentley, M, Borgheti-Cardoso, Livia Neves, Viegas, Juliana Santos Rosa, Silvestrini, Ana Vitoria Pupo, Caron, Angelo Luis, Praça, Fabiola Garcia, Kravicz, Marcelo, and Bentley, Maria Vitória Lopes Badra
- Abstract
Skin cancer is a high burden disease with a high impact on global health. Conventional therapies have several drawbacks; thus, the development of effective therapies is required. In this context, nanotechnology approaches are an attractive strategy for cancer therapy because they enable the efficient delivery of drugs and other bioactive molecules to target tissues with low toxic effects. In this review, nanotechnological tools for skin cancer will be summarized and discussed. First, pathology and conventional therapies will be presented, followed by the challenges of skin cancer therapy. Then, the main features of developing efficient nanosystems will be discussed, and next, the most commonly used nanoparticles (NPs) described in the literature for skin cancer therapy will be presented. Subsequently, the use of NPs to deliver chemotherapeutics, immune and vaccine molecules and nucleic acids will be reviewed and discussed as will the combination of physical methods and NPs. Finally, multifunctional delivery systems to codeliver anticancer therapeutic agents containing or not surface functionalization will be summarized.
- Published
- 2020
4. Therapeutic applications and delivery systems for triptolide
- Author
-
Viegas, J, Praça, F, Kravicz, M, Bentley, M, Viegas, Juliana Santos Rosa, Praça, Fabíola Garcia, Kravicz, Marcelo, Bentley, Maria Vitoria Lopes Badra, Viegas, J, Praça, F, Kravicz, M, Bentley, M, Viegas, Juliana Santos Rosa, Praça, Fabíola Garcia, Kravicz, Marcelo, and Bentley, Maria Vitoria Lopes Badra
- Abstract
Triptolide (TPL) is a natural compound and active component ofTripterygium wilfordiiHook F., an Asian native woody vine widely used for over 200 years in Chinese medicine. Hot water, ethanol-ethyl acetate, and chloroform-methanol extracts are the first reported TPL preparations in the literature, and since then, several studies for application in inflammation processes and cancer are described due to the antitumor, anti-inflammatory, and immunosuppressive characteristics of the molecule. However, physicochemical properties such as poor solubility and bioavailability are the main concerns regarding the TPL safety and efficacy in clinical studies since trials have reported adverse side effects alongside the excellent TPL therapeutic effects. Here, we review the main TPL applications and issues related to the drug usage, and a comprehensive summary of diseases is provided. Special emphasis is given to drug delivery systems designed to overcome the TPL physicochemical characteristics such as poor drug solubility, and how to increase efficacy and obtain a safe drug profile.
- Published
- 2020
5. Anaphylaxis to povidone in a child
- Author
-
Pedrosa, C., Costa, H., Oliveira, G., Romariz, J., and Praça, F.
- Published
- 2005
6. Self-reported drug allergy in a general adult Portuguese population
- Author
-
Gomes, E., Cardoso, M. F., Praça, F., Gomes, L., Mariño, E., and Demoly, P.
- Published
- 2004
7. Current Non-viral siRNA Delivery Systems as a Promising Treatment of Skin Diseases
- Author
-
Rosa, J, Suzuki, I, Kravicz, M, Caron, A, Pupo, A, Praça, F, Bentley, M, Rosa, Juliana, Suzuki, Isabella, Kravicz, Marcelo, Caron, Angelo, Pupo, Ana Vitória, Praça, Fabíola Garcia, Bentley, Maria Vitória Lopes Badra, Rosa, J, Suzuki, I, Kravicz, M, Caron, A, Pupo, A, Praça, F, Bentley, M, Rosa, Juliana, Suzuki, Isabella, Kravicz, Marcelo, Caron, Angelo, Pupo, Ana Vitória, Praça, Fabíola Garcia, and Bentley, Maria Vitória Lopes Badra
- Abstract
Background: Gene therapy is a new approach to discover and treat many diseases. It has attracted considerable attention from researchers in the last decades. The gene therapy through RNA interference has been considered one of the most recent and revolutionary approaches used in individualized therapy. In the last years, we have witnessed the rapid development in the field of the gene silencing and knockdown by topical siRNA. Its application in gene therapy has become an attractive alternative for drug development.Methods: This article will address topical delivery of siRNA as a promising treatment for skin disorders. An update on the advances in siRNA-based nanocarriers as a powerful therapeutic strategy for several skin diseases will be discussed giving emphasis on in vitro evaluations.Results: Through the in-depth review of the literature on the use of siRNAs for skin diseases we realize how widespread this use is. We have also realized that nanoparticles as non-viral vectors are increasingly being explored. Skin diseases where the use of siRNA has been explored most are skin cancer (melanoma and non-melanoma), psoriasis, vitiligo, dermatitis and leprosy. But we also report here other diseases where the use of siRNA has been growing as acne, alopecia areata, cutaneous leishmaniasis, mycoses, herpes, epidermolysis bullosa and oculocutaneous albinism. Also highlighted, the first clinical trial of siRNA for cutaneous diseases, aimed at Pathyounychia Congenita.Conclusion: The treatment of skin diseases based on topical delivery of siRNA, which act by inhibiting the expression of target transcripts, offers many potential therapeutic advantages for suppressing genes into the skin.
- Published
- 2018
8. Liquid Crystalline Nanodispersions Functionalized with Cell-Penetrating Peptides for Topical Delivery of Short-Interfering RNAs: A Proposal for Silencing a Pro-Inflammatory Cytokine in Cutaneous Diseases
- Author
-
Petrilli, R., primary, Eloy, J. O., additional, Praça, F. S. G., additional, Ciampo, J. O. Del, additional, Fantini, M. A. C., additional, Fonseca, M. J. V., additional, and Bentley, M. V. L. B., additional
- Published
- 2016
- Full Text
- View/download PDF
9. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis
- Author
-
Juliana Santos Rosa Viegas, Ana Vitoria Pupo Silvestrini, Fabíola Silva Garcia Praça, Angelo Luis Caron, Isabella Suzuki, Marcelo Kravicz, Wanessa Silva Garcia Medina, José Orestes Del Ciampo, Maria Vitória Lopes Badra Bentley, Viegas, J, Praça, F, Caron, A, Suzuki, I, Silvestrini, A, Medina, W, Del Ciampo, J, Kravicz, M, and Bentley, M
- Subjects
Male ,medicine.medical_treatment ,Down-Regulation ,Pharmaceutical Science ,02 engineering and technology ,Pharmacology ,Administration, Cutaneous ,030226 pharmacology & pharmacy ,Tacrolimus ,Mice ,03 medical and health sciences ,FÁRMACOS IMUNOSSUPRESSORES ,Gene therapy ,Nanoparticle ,0302 clinical medicine ,In vivo ,Psoriasis ,medicine ,Animals ,Viability assay ,Particle Size ,RNA, Small Interfering ,Psoriasi ,Mice, Inbred BALB C ,Imiquimod ,Tumor Necrosis Factor-alpha ,Chemistry ,Drug Synergism ,021001 nanoscience & nanotechnology ,medicine.disease ,Controlled release ,Topical application ,Calcineurin ,Disease Models, Animal ,Cytokine ,Delayed-Action Preparations ,Tacrolimu ,Liposomes ,NIH 3T3 Cells ,Nanoparticles ,Female ,Tumor necrosis factor alpha ,0210 nano-technology - Abstract
Since psoriasis is an immuno-mediated skin disease, long-term therapies are necessary for its treatment. In clinical investigations, tacrolimus (TAC), a macrolide immunosuppressive inhibitor of calcineurin, arises as an alternative for the treatment of psoriasis, acting in some cytokines involved in the pathogenesis of the disease. Here, we aim to study the psoriasis treatment with TAC and siRNA for one of most cytokines expressed in psoriasis, the TNF-alpha. A multifunctional nanostructure lipid carrier (NLC) was developed to co-delivery TAC and siRNA. Results showed that the particle size and zeta potential were around 230 nm and + 10 mV, respectively. The release study demonstrated a controlled release of TAC, and the permeation and retention profile in the skin tissue show to be promising for topical application. The cell viability and uptake in murine fibroblast presented low toxicity associated to uptake of NLC in 4 h, and finally, the in vivo animal model demonstrates the efficiency of the NLC multifunctional, exhibiting a reduction of the cytokine TNF-alpha expression about 7-fold and presenting a synergic effect between the TAC and TNF-alpha siRNA. The developed system was successfully to treat in vivo psoriatic animal model induced by imiquimod and the synergic combination was reported here for the first time.Graphical abstract
- Published
- 2020
10. Therapeutic applications and delivery systems for triptolide
- Author
-
Marcelo Kravicz, Maria Vitória Lopes Badra Bentley, Juliana Santos Rosa Viegas, Fabíola Silva Garcia Praça, Viegas, J, Praça, F, Kravicz, M, and Bentley, M
- Subjects
Drug ,Cancer therapy ,ARTRITE REUMATOIDE ,Tripterygium ,media_common.quotation_subject ,Drug delivery system ,Pharmaceutical Science ,02 engineering and technology ,Traditional Chinese medicine ,Pharmacology ,030226 pharmacology & pharmacy ,Drug usage ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Medicine ,Adverse effect ,Rheumatoid arthriti ,media_common ,Psoriasi ,biology ,Triptolide ,business.industry ,Phenanthrenes ,021001 nanoscience & nanotechnology ,biology.organism_classification ,Bioavailability ,chemistry ,Drug delivery ,Tripterygium wilfordii ,Epoxy Compounds ,Diterpenes ,0210 nano-technology ,business ,Drugs, Chinese Herbal - Abstract
Triptolide (TPL) is a natural compound and active component of Tripterygium wilfordii Hook F., an Asian native woody vine widely used for over 200 years in Chinese medicine. Hot water, ethanol-ethyl acetate, and chloroform-methanol extracts are the first reported TPL preparations in the literature, and since then, several studies for application in inflammation processes and cancer are described due to the antitumor, anti-inflammatory, and immunosuppressive characteristics of the molecule. However, physicochemical properties such as poor solubility and bioavailability are the main concerns regarding the TPL safety and efficacy in clinical studies since trials have reported adverse side effects alongside the excellent TPL therapeutic effects. Here, we review the main TPL applications and issues related to the drug usage, and a comprehensive summary of diseases is provided. Special emphasis is given to drug delivery systems designed to overcome the TPL physicochemical characteristics such as poor drug solubility, and how to increase efficacy and obtain a safe drug profile. Graphical abstract.
- Published
- 2020
11. Nanotechnology approaches in the current therapy of skin cancer
- Author
-
Angelo Luis Caron, Ana Vitoria Pupo Silvestrini, Maria Vitória Lopes Badra Bentley, Marcelo Kravicz, Fabíola Silva Garcia Praça, Lívia Neves Borgheti-Cardoso, Juliana Santos Rosa Viegas, Borgheti-Cardoso, L, Viegas, J, Silvestrini, A, Caron, A, Praça, F, Kravicz, M, and Bentley, M
- Subjects
Skin Neoplasms ,Surface Properties ,Skin Absorption ,Bioactive molecules ,medicine.medical_treatment ,Drug delivery system ,Cancer therapy ,Metal Nanoparticles ,Pharmaceutical Science ,Antineoplastic Agents ,Nanotechnology ,Context (language use) ,02 engineering and technology ,Disease ,Administration, Cutaneous ,Nanocarrier design ,03 medical and health sciences ,Gene therapy ,Multifunctional delivery system ,Nonmelanoma skin cancer ,Skin Physiological Phenomena ,Humans ,Medicine ,Skin cancer ,Particle Size ,Melanoma ,Càncer de pell ,030304 developmental biology ,Drug Carriers ,0303 health sciences ,business.industry ,Nanotecnologia ,Melanoma skin cancer ,Immunotherapy ,021001 nanoscience & nanotechnology ,medicine.disease ,Dacarbazine ,Drug Resistance, Neoplasm ,IMUNOTERAPIA ,Nanoparticles ,Fluorouracil ,Gold ,0210 nano-technology ,business - Abstract
Skin cancer is a high burden disease with a high impact on global health. Conventional therapies have several drawbacks; thus, the development of effective therapies is required. In this context, nanotechnology approaches are an attractive strategy for cancer therapy because they enable the efficient delivery of drugs and other bioactive molecules to target tissues with low toxic effects. In this review, nanotechnological tools for skin cancer will be summarized and discussed. First, pathology and conventional therapies will be presented, followed by the challenges of skin cancer therapy. Then, the main features of developing efficient nanosystems will be discussed, and next, the most commonly used nanoparticles (NPs) described in the literature for skin cancer therapy will be presented. Subsequently, the use of NPs to deliver chemotherapeutics, immune and vaccine molecules and nucleic acids will be reviewed and discussed as will the combination of physical methods and NPs. Finally, multifunctional delivery systems to codeliver anticancer therapeutic agents containing or not surface functionalization will be summarized.
- Published
- 2020
12. Current Non-viral siRNA Delivery Systems as a Promising Treatment of Skin Diseases
- Author
-
Maria Vitória Lopes Badra Bentley, Angelo Luis Caron, Marcelo Kravicz, Fabíola Silva Garcia Praça, Ana Vitória Pupo, Juliana dos Santos Rosa, Isabella Suzuki, Rosa, J, Suzuki, I, Kravicz, M, Caron, A, Pupo, A, Praça, F, and Bentley, M
- Subjects
0301 basic medicine ,Small interfering RNA ,Vitiligo ,Bioinformatics ,Skin Diseases ,non-viral vector ,03 medical and health sciences ,Drug Delivery Systems ,Psoriasis ,Drug Discovery ,medicine ,Animals ,Humans ,Gene silencing ,RNA, Small Interfering ,Acne ,Pharmacology ,skin disease ,integumentary system ,business.industry ,nanoparticle ,Gene Therapy ,medicine.disease ,drug development ,RNAi Therapeutics ,030104 developmental biology ,Drug development ,siRNA ,Epidermolysis bullosa ,Skin cancer ,business - Abstract
Background: Gene therapy is a new approach to discover and treat many diseases. It has attracted considerable attention from researchers in the last decades. The gene therapy through RNA interference has been considered one of the most recent and revolutionary approaches used in individualized therapy. In the last years, we have witnessed the rapid development in the field of the gene silencing and knockdown by topical siRNA. Its application in gene therapy has become an attractive alternative for drug development. Methods: This article will address topical delivery of siRNA as a promising treatment for skin disorders. An update on the advances in siRNA-based nanocarriers as a powerful therapeutic strategy for several skin diseases will be discussed giving emphasis on in vitro evaluations. Results: Through the in-depth review of the literature on the use of siRNAs for skin diseases we realize how widespread this use is. We have also realized that nanoparticles as non-viral vectors are increasingly being explored. Skin diseases where the use of siRNA has been explored most are skin cancer (melanoma and nonmelanoma), psoriasis, vitiligo, dermatitis and leprosy. But we also report here other diseases where the use of siRNA has been growing as acne, alopecia areata, cutaneous leishmaniasis, mycoses, herpes, epidermolysis bullosa and oculocutaneous albinism. Also highlighted, the first clinical trial of siRNA for cutaneous diseases, aimed at Pathyounychia Congenita. Conclusion: The treatment of skin diseases based on topical delivery of siRNA, which act by inhibiting the expression of target transcripts, offers many potential therapeutic advantages for suppressing genes into the skin.
- Published
- 2018
13. Liquid crystalline nanoparticles enable a multifunctional approach for topical psoriasis therapy by co-delivering triptolide and siRNAs.
- Author
-
Silvestrini AVP, Garcia Praça F, Leite MN, de Abreu Fantini MC, Frade MAC, and Badra Bentley MVL
- Subjects
- Swine, Animals, RNA, Small Interfering, Tumor Necrosis Factor-alpha, Interleukin-6, Scattering, Small Angle, X-Ray Diffraction, Psoriasis drug therapy, Nanoparticles chemistry
- Abstract
Liquid crystalline nanoparticles (LCNs) are an attractive drugs topical delivery system due to the great internal ordering, wide interfacial area and structural similarities with the skin. In this work, LCNs were designed to encapsulate triptolide (TP) and to complex on its surface small interfering RNAs (siRNA) targeting TNF-α and IL-6, aiming at topical co-delivery and regulating multi-targets in psoriasis. These multifunctional LCNs showed appropriate physicochemical properties for topical application, such as a mean size of 150 nm, low polydispersion, TP encapsulation greater than 90% and efficient complexation with siRNA. The internal reverse hexagonal mesostructure of LCNs was confirmed by SAXS while their morphology was assessed by cryo-TEM. In vitro permeation studies revealed an increase of more than 20-fold in the distribution of TP through the porcine epidermis/dermis was achieved after the application of LCN-TP or LCN TP in hydrogel. In cell culture, LCNs showed good compatibility and rapid internalization, which was attributed to macropinocytosis and caveolin-mediated endocytosis. Anti-inflammatory potential of multifunctional LCNs was assessed by reducing of TNF-α, IL-6, IL-1β and TGF-β1 levels in LPS-stimulated macrophages. These results support the hypothesis that the co-delivery of TP and siRNAs by LCNs may be a new strategy for psoriasis topical therapy., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Progress and challenges of lyotropic liquid crystalline nanoparticles for innovative therapies.
- Author
-
Vitoria Pupo Silvestrini A, Wender Debiasi B, Garcia Praça F, and Vitoria Lopes Badra Bentley M
- Subjects
- Peptides, Therapies, Investigational, Liquid Crystals chemistry, Nanoparticles chemistry, Nucleic Acids
- Abstract
Since the late 20th century, we have witnessed a growing and substantial advance in nanomedicine, in part due to the development of multifunctional and multimodal nanoplatforms that have enabled improved efficacy, biocompatibility, and novel therapeutic applications. Non-lamellar liquid-crystalline nanoparticles, especially, reverse hexagonal and cubic bicontinuous mesophases, have gained the attention of the scientific-academic community due to their intriguing and functional characteristics, such as self-organization into two- and three-dimensional supramolecular structures, high symmetry, and ability to accommodate hydrophobic and hydrophilic small molecules, peptides, proteins, nucleic acids, and imaging agents. Furthermore, these particles can be easily modified with specific and/or bioresponsive molecules allowing targeting and improved therapeutic performance. In this contribution we provide an overview of advances in the design and architecture of LCNPs, strategies to overcome biological barriers and main findings about interactions with different types of interfaces. We highlight recent applications in topical, oral, pulmonary and intravenous drug delivery in preclinical in vivo studies. We discussed the current scenario and translational obstacles faced for clinical translation, as well as our perspectives., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.